Epigenetic silencing of the MGMT gene in cancer

Biochemistry and Cell Biology

Volumn 83, Issue 4, 2005, Pages 429-437

  Soejima, Hidenobu ^a   Zhao, Wei ^a   Mukai, Tsunehiro ^a  

^a SAGA UNIVERSITY   (Japan)

Author keywords

Cancer; DNA methylation; DNA repair; Heterochromatin; Histone modification; MBD protein

Indexed keywords

ALKYLATION; BIOCHEMISTRY; CHEMOTHERAPY; DNA; ENZYMES; GENETIC ENGINEERING; TUMORS;

DNA METHYLATION; DNA REPAIR; HETEROCHROMATIN; HISTONE MODIFICATION; MBD PROTEIN;

GENES;

ALKYLATING AGENT; METHYL CPG BINDING PROTEIN; METHYL GROUP; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; THYMINE; DNA BINDING PROTEIN; HISTONE;

BASE MISPAIRING; CANCER; CANCER CHEMOTHERAPY; CARCINOGENESIS; CONFERENCE PAPER; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA REPAIR; DNA REPLICATION; GENE; GENE MUTATION; GENE SILENCING; GENETIC EPIGENESIS; HUMAN; HUMAN CELL; MGMT GENE; NUCLEOTIDE SEQUENCE; PROGNOSIS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; PHYSIOLOGY; REVIEW;

CPG ISLANDS; DNA METHYLATION; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HISTONES; HUMANS; NEOPLASMS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE;

EID: 27744495771     PISSN: 08298211     EISSN: None     Source Type: Journal    
DOI: 10.1139/o05-140     Document Type: Conference Paper

References (79)

1. 6 methylguanine mediated carcinogenic mutations to threshold levels after N-methyl-N-nitrosourea. Oncogene, 18: 3783-3787.
2. Ballestar, E., Paz, M.F., Valle, L., Wei, S., Fraga, M.F., Espada, J. et al. 2003. Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J. 22: 6335-645.
3. Becker, K., Dosch, J., Gregel, C.M., Martin, B.A., and Kaina, B. 1996. Targeted expression of human O(6)-methylguanine-DNA methyltransferase (MGMT) in transgenic mice protects against tumor initiation in two-stage skin carcinogenesis. Cancer Res. 56: 3244-3249.
4. Burgers, W.A., Fuks, F., and Kouzarides, T. 2002. DNA methyltransferases get connected to chromatin. Trends Genet. 18: 275-277.
5. Chan, E.C., Lam, S.Y., Tsang, K.W., Lam, B., Ho, J.C., Fu, K.H. et al. 2002. Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalveolar lavage. Clin. Cancer Res. 8: 3741-3746.
6. 6-methylguanine-DNA methyltransferase in human normal and tumor tissue from brain, lung, and ovary. Cancer Res. 51: 4131-4134.
7. 6-methylguanine-DNA methyltransferase gene MGMT in human normal and tumor tissues. J. Natl. Cancer Inst. 84: 3373-3340.
8. Costello, J.F., Futscher, B.W., Kroes, R.A., and Pieper, R.O. 1994a. Methylation-related chromatin structure is associated with exclusion of transcription factors from and suppressed expression of the O-6-methylguanine DNA methyltransferase gene in human glioma cell lines. Mol. Cell. Biol. 14: 6515-6521.
9. 6- methylguanine DNA methyltransferase (MGMT) gene correlates with MGMT expression in human glioma cells. J. Biol. Chem. 269: 17228-17237.
10. Danam, R.P., Howell, S.R., Brent, T.P., and Harris, L.C. 2005. Epigenetic regulation of O6-methylguanine-DNA methyltransferase gene expression by histone acetylation and methyl-CpG binding proteins. Mol. Cancer Ther. 4: 61-69.
11. Dillon, N. 2004. Heterochromatin structure and function. Biol. Cell 96: 631-637.
12. Dillon, N., and Festenstein, R. 2002. Unravelling heterochromatin: competition between positive and negative factors regulates accessibility. Trends Genet. 18: 252-258.
13. 6-methylguanine-DNA methyltransferase SNPs: a frequency comparison of patients with familial melanoma and healthy individuals in Sweden. Hum. Mutat. 20: 408-409.
14. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 59: 793-797.
15. Esteller, M., Sanchez-Cespedes, M., Rosell, R., Sidransky, D., Baylin, S.B., and Herman, J.G. 1999a. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59: 67-70.
16. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res. 60: 2368-2371.
17. Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S.N., Hidalgo, O.F., Vanaclocha, V. et al. 2000b. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343: 1350-1354
18. 6-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res. 61: 4689-4692.
19. Esteller, M., Gaidano, G., Goodman, S.N., Zagonel, V., Capello, D., Botto, B. et al. 2002. Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J. Natl. Cancer Inst. 94: 26-32.
20. Fahrner, J.A., Eguchi, S., Herman, J.G., and Baylin, S.B. 2002. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res. 62: 7213-7218.
21. Fujita, N., Watanabe, S., Ichimura, T., Tsuruzoe, S., Shinkai, Y., Tachibana, M. et al. 2003. Methyl-CpG binding domain 1 (MBD1) interacts with the Suv39h1-HP1 heterochromatic complex for DNA methylation-based transcriptional repression. J. Biol. Chem. 278: 24132-24138.
22. Fujiwara, K., Fujimoto, N., Tabata, M., Nishii, K., Matsuo, K., Hotta, K. et al. 2005. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin. Cancer Res. 11: 1219-1225.
23. Fuks, F., Burgers, W.A., Brehm, A., Hughes-Davies, L., and Kouzarides, T. 2000. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat. Genet. 24: 88-91.
24. Fuks, F., Burgers, W.A., Godin, N., Kasai, M., and Kouzarides, T. 2001. Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. EMBO J. 20: 2536-2544.
25. Fuks, F., Hurd, P.J., Wolf, D., Nan, X., Bird, A.P., and Kouzarides, T. 2003a. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J. Biol. Chem. 278: 4035-4040.
26. Fuks, F., Hurd, P.J., Deplus, R., and Kouzarides, T. 2003b. The DNA methyltransferases associate with HP1 and the SUV39H1 histone methyltransferase. Nucleic Acids Res. 31: 2305-2312.
27. Gardiner-Garden, M., and Frommer, M. 1987. CpG islands in vertebrate genomes. J. Mol. Biol. 196: 261-282.
28. Gerson, S.L. 2004. MGMT: its role in cancer aetiology and cancer therapeutics. Nat. Rev. Cancer, 4: 296-307.
29. Grewal, S.I., and Moazed, D. 2003. Heterochromatin and epigenetic control of gene expression. Science (Wash. D.C.), 301: 798-802.
30. 6-methylguanine-DNA methyltransferase gene. Nucleic Acids Res. 19: 6163-6167.
31. 6-methylguanine DNA methyltransferase gene. Nucleic Acids Res. 22: 4614-4619.
32. Hegi, M.E., Diserens, A.C., Gorlia, T., Hamou, M.F., de Tribolet, N., Weller, M. et al. 2005. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352: 997-1003.
33. Herfarth, K.K., Brent, T.P., Danam, R.P., Remack, J.S., Kodner, I.J., Wells, S.A., Jr., and Goodfellow, P.J. 1999. A specific CpG methylation pattern of the MGMT promoter region associated with reduced MGMT expression in primary colorectal cancers. Mol. Carcinog. 24: 90-98.
34. Herman, J.G., and Baylin, S.B. 2003. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349: 2042-2054.
35. 6-methylguanine-DNA methyltransferase gene in young patients with adult type cancers and functional assay. Carcinogenesis, 16: 2441-2445.
36. Inoue, R., Abe, M., Nakabeppu, Y., Sekiguchi, M., Mori, T., and Suzuki, T. 2000. Characterization of human polymorphic DNA repair methyltransferase. Pharmacogenetics, 10: 59-66.
37. Iwakuma, T., Sakumi, K., Nakatsuru, Y., Kawate, H., Igarashi, H., Shiraishi, A. et al. 1997. High incidence of nitrosamine-induced tumorigenesis in mice lacking DNA repair methyltransferase. Carcinogenesis, 18: 1631-1635.
38. Jaenisch, R., and Bird, A. 2003. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat. Genet. 33: 245-254.
39. Jenuwein, T., and Allis, C.D. 2001. Translating the histone code. Science (Wash. D.C.), 293: 1074-1080.
40. Jones, P.A., and Baylin S.B. 2002. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3: 415-428.
41. Jones, P.A., and Laird P.W. 1999. Cancer epigenetics comes of age. Nat. Genet. 21: 163-167.
42. 6-alkylguanine DNA alkyltransferase gene in lung cancer risk. Cancer Epidemiol. Biomark. Prev. 9: 3393-3342.
43. 6-methylguanine-DNA methyltransferase in human biliary tract cancers. Ann. Surg. Oncol. 12: 354-363.
44. Kohya, N., Miyazaki, K., Matsukura, S., Yakushiji, H., Kitajima, Y., Kitahara, K. et al. 2002. Deficient expression of O(6)-methylguanine-DNA methyltransferase combined with mismatch-repair proteins hMLH1 and hMSH2 is related to poor prognosis in human biliary tract carcinoma. Ann. Surg. Oncol. 9: 371-379.
45. Kondo, Y., Shen, L., and Issa, J.P. 2003. Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol. Cell. Biol. 23: 206-215.
46. Kouskouti, A., and Talianidis, I. 2005. Histone modifications defining active genes persist after transcriptional and mitotic inactivation. EMBO J. 24: 347-357.
47. Lachner, M., and Jenuwein, T. 2002. The many faces of histone lysine methylation. Curr. Opin. Cell Biol. 14: 286-298.
48. 6-methylguanine-DNA methyltransferase in hepatocellular, gastric, and breast cancers. Ann. Surg. Oncol. 8: 807-816.
49. 6-methylguanine- DNA methyltransferase and hMLH1 accelerates progression of hepatocellular carcinoma. J. Surg. Oncol. 82: 194-200.
50. Nakagawachi, T., Soejima, H., Urano, T., Zhao, W., Higashimoto, K., Satoh, Y. et al. 2003. Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer. Oncogene, 22: 8835-8844.
51. 6-methylguanine to a protein cysteine residue. J. Biol. Chem. 255: 10569-10571.
52. Palmisano, W.A., Divine, K.K., Saccomanno, G., Gilliland, F.D., Baylin, S.B., Herman, J.G., and Belinsky, S.A. 2000. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 60: 5954-5958.
53. 6-methylguanine DNA methyltransferase gene is associated with the loss of nucleosome-like positioning. Mol. Cell. Biol. 17: 5813-5822.
54. Paz, M.F., Yaya-Tur, R., Rojas-Marcos, I., Reynes, G., Pollan, M., Aguirre-Cruz, L. et al. 2004. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin. Cancer Res. 10: 4933-4938.
55. Peters, A.H., Kubicek, S., Mechtler, K., O'Sullivan, R.J., Derijck, A.A., Perez-Burgos, L. et al. 2003. Partitioning and plasticity of repressive histone methylation states in mammalian chromatin. Mol. Cell 12: 1577-1589.
56. Pieper, R.O., Patel, S., Ting, S.A., Futscher, B.W., and Costello, J.F. 1996. Methylation of CpG island transcription factor binding sites is unnecessary for aberrant silencing of the human MGMT gene. J. Biol. Chem. 271: 13916-13924.
57. Plath, K., Fang, J., Mlynarczyk-Evans, S.K., Cao, R., Worringer, K.A., Wang, H. et al. 2003. Role of histone H3 lysine 27 methylation in X inactivation. Science (Wash. D.C.), 300: 131-135.
58. 6-methylguanine-DNA methyltransferase gene. Cancer Res. 57: 3672-3677.
59. Rhee, I., Jair, K.W., Yen, R.W., Lengauer, C., Herman, J.G., Kinzler, K.W. et al. 2000. CpG methylation is maintained in human cancer cells lacking DNMT1. Nature (London), 404: 1003-1007.
60. Rhee, I., Bachman, K.E., Park, B.H., Jair, K.W., Yen, R.W., Schuebel, K.E. et al. 2002. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (London), 416: 552-556.
61. Rice, J.C., Briggs, S.D., Ueberheide, B., Barber, C.M., Shabanowitz, J., Hunt, D.F. et al. 2003. Histone methyltransferases direct different degrees of methylation to define distinct chromatin domains. Mol. Cell, 12: 1591-1598.
62. Robertson, K.D., Ait-Si-Ali, S., Yokochi, T., Wade, P.A., Jones, P.L., and Wolffe, A.P. 2000. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat. Genet. 25: 338-342.
63. 6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res. 61: 939-942.
64. Rountree, M.R., Bachman, K.E., and Baylin, S.B. 2000. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat. Genet. 25: 269-277.
65. Rusin, M., Samojedny, A., Harris, C.C., and Chorazy, M. 1999. Novel genetic polymorphisms in DNA repair genes: O(6)-methylguanine-DNA methyltransferase (MGMT) and N-methylpurine-DNA glycosylase (MPG) in lung cancer patients from Poland. Hum. Mutat. 14: 269-270.
66. Sakumi, K., Shiraishi, A., Shimizu, S., Tsuzuki, T., Ishikawa, T., and Sekiguchi, M. 1997. Methylnitrosourea-induced tumorigenesis in MGMT gene knockout mice. Cancer Res. 57: 2415-2418.
67. Sanchez-Cespedes, M., Esteller, M., Wu, L., Nawroz-Danish, H., Yoo, G.H., Koch, W.M. et al. 2000. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res. 60: 892-895.
68. Santos-Rosa, H., Schneider, R., Bannister, A.J., Sherriff, J., Bernstein, B.E., Emre, N.C. et al. 2002. Active genes are trimethylated at K4 of histone H3. Nature (London), 419: 407-411.
69. Sato, K., Kitajima, Y., Nakagawachi, T., Soejima, H., Miyoshi, A., Koga, Y., and Miyazaki, K. 2005. Cisplatin represses transcriptional activity from the minimal promoter of the O(6)-methylguanine methyltransferase gene and increases sensitivity of human gallbladder cancer cells to 1-(4-amino-2-methyl-5- pyrimidinyl) methyl-3-2-chloroethyl)-3-nitrosourea. Oncol. Rep. 13: 899-906.
70. Schneider, R., Bannister, A.J., Myers, F.A., Thorne, A.W., Crane-Robinson, C., and Kouzarides, T. 2004. Histone H3 lysine 4 methylation patterns in higher eukaryotic genes. Nat. Cell Biol. 6: 73-77.
71. Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J.R., Cole, P.A. et al. 2004. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell, 119: 941-953.
72. Silva, J., Mak, W., Zvetkova, I., Appanah, R., Nesterova, T.B., Webster, Z. et al. 2003. Establishment of histone h3 methylation on the inactive X chromosome requires transient recruitment of Eed-Enx1 polycomb group complexes. Dev. Cell 4: 481-495.
73. Soejima, H., Joh, K., and Mukai, T. 2004. Gene silencing in DNA damage repair. Cell. Mol. Life Sci. 61: 2168-2172.
74. 6-benzylguanine or 1,3-bis(2-chloroethyl)-1-nitrosourea. Biochemistry, 35: 1328-1334.
75. Takai, D., and Jones, P.A. 2002. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc. Natl. Acad. Sci. U.S.A. 99: 3740-3745.
76. Tate, P.H., and Bird, A.P. 1993. Effects of DNA methylation on DNA-binding proteins and gene expression. Curr. Opin. Genet. Dev. 3: 226-231.
77. 6-methylguanine-DNA methyltransferase gene in esophageal cancer tissues from Northern China. Int. J. Cancer, 71: 719-723.
78. 6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol. Cell. Biol. 17: 5612-5619.
79. Zhao, W., Soejima, H., Higashimoto, K., Nakagawachi, T., Urano, T., Kudo, S. et al. 2005. The essential role of histone H3 lys9 methylation and MeCP2 binding in MGMT silencing with poor DNA methylation of the promoter CpG island. J. Biochem. (Tokyo) 137: 431-440.